FINWIRES · TerminalLIVE
FINWIRES

Indian Equities End Higher on Wednesday Amid Positive Fiscal Q4 Earnings

By

-- Indian benchmark indices ended higher on Wednesday, supported by positive fiscal Q4 earnings and value buying across select sectors.

A large part of intraday gains was, however, trimmed in late trade due to profit booking.

The BSE Sensex rose 609.45 points, or 0.8%, to close at 77,496.36, while the NSE Nifty 50 gained 181.95 points, or also 0.8%, to settle at 24,177.65.

The market saw early support from selective buying, especially in auto stocks, which helped indices move higher in morning trade. However, the momentum was lost later as investors locked in gains at higher levels.

Rising crude oil prices also kept sentiment in check amid concerns about supply disruptions if the Strait of Hormuz remains closed for longer period.

Among stocks, Vedanta (NSE:VEDL, BOM:500295) rose nearly 5% after reporting a sharp jump in fiscal Q4 profit to 67.0 billion rupees from 34.8 billion rupees a year earlier.

Shelter Pharma (BOM:543963) gained nearly 4% after securing a $144,000 export order for pharmaceutical supplies.

Related Articles

Research

Research Alert: Regn Posts Strong Q1 Fueled By Dupixent And Eylea Hd Amid Manufacturing Issues

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Regeneron delivered robust Q1 2026 results with total revenues of $3.6B (+19% Y/Y) and non-GAAP EPS of $9.47 (+15% Y/Y), beating consensus estimates. The EYLEA franchise continues to transition from traditional EYLEA to EYLEA HD, with HD sales reaching $468M (+52% Y/Y) while traditional sales declined to $473M (-36% Y/Y) due to biosimilar competition. We view the underlying portfolio strength as encouraging, with Dupixent maintaining exceptional momentum at global sales of $4.9B (+33% Y/Y) and physician unit demand for EYLEA HD increasing 10% sequentially despite inventory normalization. Management expects manufacturing disruptions at the Limerick facility to normalize by the end of Q2, lowering full-year GAAP gross margin guidance to 77%-78%. We believe the company's diversified revenue base and deep pipeline of nearly 50 clinical programs, including the recent Otarmeni approval and advancing Factor XI antibody Phase 3 studies, position REGN well for continued growth despite near-term manufacturing headwinds.

$REGN
Asia

Rita Finance and Leasing Names CFO

Rita Finance and Leasing (BOM:543256, NSE:RFLL) appointed Mukesh Laxman Sharma as chief financial officer of the company, effective Wednesday, according to a same-day filing on Indian bourses.

$BOM:543256$NSE:RFLL
Asia

Sterlite Technologies Returns to Profit in Fiscal Q4

Sterlite Technologies (NSE:STLTECH, BOM:532374) returned to attributable consolidated net profit of 590 million Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 400 million rupees a year ago.Earnings per share stood at 1.17 rupees compared with a loss per share of 0.84 rupees, according to a Wednesday filing by the optic fiber cables manufacturer to the stock exchanges.Revenue from operations in fiscal Q4 increased to 14.4 billion rupees from 10.5 billion rupees a year earlier.

$BOM:532374$NSE:STLTECH